Background
The aim of this work is to evaluate the efficacy and safety of imiquimod 5% cream used in the treatment of certain non-melanoma skin cancers.
Materials and methods
We treated 30 subjects: 5 actinic keratosis, 3 cheratoacanthomas, 5 cutaneous horns, 5 superficial basal cell carcinomas, 12 nodular basal cell carcinomas according to the therapeutic pattern -five applications a week for 6-12 weeks. The patients with nodular forms could not be treated with surgery for severe chronic deseases, age, or refusal.
Results
Imiquimod 5% cream was effective and well tolerated both in actinic keratosis and in superficial and nodular basal cell carcinoma.
Conclusions
The treatment of certain non-melanoma coutaneous toumors with imiquimod 5% cream, has been effective, without collateral effects; erythema, edema, vesicles, crusts and erosions with itching or burning in the application area, have been the most frequent adverse events which however did not cause the suspension of therapy.
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